TEVA · NYSE
Teva Pharmaceutical Industries Limited
$39.40 -0.86 (-2.14%)
Company overview
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products worldwide. The company offers a broad range of products including sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. Teva also develops, manufactures, and sells active pharmaceutical ingredients. The company focuses on central nervous system, pain, respiratory, and oncology therapeutic areas. Its CNS products include Copaxone for relapsing forms of multiple sclerosis, AJOVY for preventive migraine treatment, and AUSTEDO for tardive dyskinesia and chorea associated with Huntington disease.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NYSE
- Market cap
- $45.9B
- Employees
- 37,000
- Headquarters
- Tel Aviv
- Website
- tevapharm.com
- CEO
- Richard D. Francis
- Listed
- February 16, 1982
- P/E
- 28.76
- Dividend yield
- 5.80%
Company financials
- Revenue
- $17.3B
- Gross profit
- $9B
- Operating income
- $2.3B
- EBITDA
- $3.3B
- Net income
- $1.6B
- EPS
- $1.37
- Total assets
- $40B
- Total debt
- $16.9B
- Gross margin
- 52.08%
- Net margin
- 9.02%
- Earnings yield
- 3.48%
Showing FY 2025
TEVA
1D
NYSE
O40.20H40.45L39.58C40.21-0.41 (-1.01%)Vol4.07M